Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COAST: OPD5 Conditioning for ASCT in RRMM
NCT04918511Phase 1Withdrawn
- Sponsor
- Oncopeptides AB
- Start
- May 2021
- Primary completion
- Mar 2024
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of OPD5 in multiple myeloma (MM) (7 cohorts), sponsored by Oncopeptides AB. Primary endpoints: Incidence and grade of Treatment Emergent Adverse Events, Incidence of clinically significant changes in clinical laboratory parameters and 4 more. Planned start May 2021; status: withdrawn.
02
Drugs
OPD5
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04918511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918511.